Biofrontera Statistics
Total Valuation
Biofrontera has a market cap or net worth of $16.64 million. The enterprise value is $19.48 million.
| Market Cap | 16.64M |
| Enterprise Value | 19.48M |
Important Dates
The last earnings date was Thursday, August 13, 2026, before market open.
| Earnings Date | Aug 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Biofrontera has 12.80 million shares outstanding. The number of shares has increased by 49.16% in one year.
| Current Share Class | 12.80M |
| Shares Outstanding | 12.80M |
| Shares Change (YoY) | +49.16% |
| Shares Change (QoQ) | +10.62% |
| Owned by Insiders (%) | 10.45% |
| Owned by Institutions (%) | 6.34% |
| Float | 9.05M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 8.13 |
| PS Ratio | 0.36 |
| Forward PS | 0.35 |
| PB Ratio | 3.10 |
| P/TBV Ratio | 4.91 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.42 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.18, with a Debt / Equity ratio of 1.26.
| Current Ratio | 1.18 |
| Quick Ratio | 0.97 |
| Debt / Equity | 1.26 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -12.78 |
Financial Efficiency
Return on equity (ROE) is -988.35% and return on invested capital (ROIC) is -55.91%.
| Return on Equity (ROE) | -988.35% |
| Return on Assets (ROA) | -17.45% |
| Return on Invested Capital (ROIC) | -55.91% |
| Return on Capital Employed (ROCE) | -45.63% |
| Weighted Average Cost of Capital (WACC) | 7.54% |
| Revenue Per Employee | $491,223 |
| Profits Per Employee | -$67,713 |
| Employee Count | 94 |
| Asset Turnover | 2.09 |
| Inventory Turnover | 3.74 |
Taxes
In the past 12 months, Biofrontera has paid $29,000 in taxes.
| Income Tax | 29,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +36.84% in the last 52 weeks. The beta is 0.80, so Biofrontera's price volatility has been lower than the market average.
| Beta (5Y) | 0.80 |
| 52-Week Price Change | +36.84% |
| 50-Day Moving Average | 1.08 |
| 200-Day Moving Average | 0.95 |
| Relative Strength Index (RSI) | 66.11 |
| Average Volume (20 Days) | 423,668 |
Short Selling Information
The latest short interest is 61,079, so 0.48% of the outstanding shares have been sold short.
| Short Interest | 61,079 |
| Short Previous Month | 24,157 |
| Short % of Shares Out | 0.48% |
| Short % of Float | 0.67% |
| Short Ratio (days to cover) | 0.15 |
Income Statement
In the last 12 months, Biofrontera had revenue of $46.18 million and -$6.37 million in losses. Loss per share was -$0.54.
| Revenue | 46.18M |
| Gross Profit | 36.60M |
| Operating Income | -6.17M |
| Pretax Income | -6.34M |
| Net Income | -6.37M |
| EBITDA | -5.97M |
| EBIT | -6.17M |
| Loss Per Share | -$0.54 |
Balance Sheet
The company has $4.67 million in cash and $7.50 million in debt, with a net cash position of -$2.84 million or -$0.22 per share.
| Cash & Cash Equivalents | 4.67M |
| Total Debt | 7.50M |
| Net Cash | -2.84M |
| Net Cash Per Share | -$0.22 |
| Equity (Book Value) | 5.96M |
| Book Value Per Share | 0.42 |
| Working Capital | 1.89M |
Cash Flow
In the last 12 months, operating cash flow was -$7.93 million and capital expenditures -$3,000, giving a free cash flow of -$7.93 million.
| Operating Cash Flow | -7.93M |
| Capital Expenditures | -3,000 |
| Depreciation & Amortization | 203,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -7.93M |
| FCF Per Share | -$0.62 |
Margins
Gross margin is 79.25%, with operating and profit margins of -13.36% and -13.78%.
| Gross Margin | 79.25% |
| Operating Margin | -13.36% |
| Pretax Margin | -13.72% |
| Profit Margin | -13.78% |
| EBITDA Margin | -12.92% |
| EBIT Margin | -13.36% |
| FCF Margin | n/a |
Dividends & Yields
Biofrontera does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -49.16% |
| Shareholder Yield | -49.16% |
| Earnings Yield | -38.24% |
| FCF Yield | -47.64% |
Analyst Forecast
The average price target for Biofrontera is $5.88, which is 352.31% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $5.88 |
| Price Target Difference | 352.31% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | 14.89% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on July 5, 2023. It was a reverse split with a ratio of 1:20.
| Last Split Date | Jul 5, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |